News

Article

FDA Grants 510(k) Clearance for Traumagel to Control Bleeding

The hemostatic gel is plant-based and designed to stop and control bleeding within seconds after applied to wound at the point of care.

This is a developing story.

The FDA granted 510(k) clearance for Traumagel (Cresilon), a temporary external drug used to control moderate-to-severe bleeding. The hemostatic gel is plant-based and designed to stop and control bleeding within seconds after applied to wound at the point of care, according to the news release.

Hospital FDA | Image Credit: spotmatikphoto -stock.adobe.com

Image Credit: spotmatikphoto -stock.adobe.com

“The ability to rapidly stop bleeding at the point of care and halt a life-threatening hemorrhage can be the difference between life and death for people with traumatic injuries,” Joe Landolina, CEO and co-founder of Cresilon, said in the news release. “The FDA clearance for Traumagel is a monumental milestone for Cresilon and brings us another step forward in our mission to save lives and transform the standard of care in emergency medicine. Our proprietary hemostatic gel technology is a game-changer and unlike any other hemostatic agent currently being used.”

Reference

Cresilon Receives FDA Clearance for TRAUMAGEL. News release. Cresilon. August 15, 2024. Accessed August 16, 2024. https://cresilon.com/2024/08/15/cresilon-receives-fda-clearance-for-traumagel/

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit:  Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit:  kitsawet | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com